Moderna (MRNA) PT Raised to $112 at BMO Capital on Interim NIAID Ph1 Results
Tweet Send to a Friend
BMO Capital analyst George Farmer raised the price target on Moderna (NASDAQ: MRNA) to $112.00 (from $83.00) after reported interim ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
